Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Healthy Male Individuals Possess Higher Plasma Her-2 Level Than Females Publisher



Fateh ST1 ; Behgozin A2 ; Yekani F2 ; Geranpayeh L3 ; Olfatbakhsh A4 ; Moghadam S4 ; Sarramiforooshani R5 ; Salehinajafabadi A2, 6 ; Shekari F2, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. R&D Division, Tashkhis Fan Firoozeh (Firoozeh DiaTech), Tehran, Iran
  3. 3. Department of Surgery, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Breast Diseases Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  5. 5. ATMP Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
  6. 6. Department of Microbiology, School of Biology, University College of Science, University of Tehran, Tehran, Iran
  7. 7. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

Source: Cell Journal Published:2023


Abstract

Considering HER2 as one of the well-known biomarkers in the cancer field, and published articles regarding serum levels of HER2, in this paper we tried to highlight the issue that most studies don’t stratify the HER-2 concentration of individuals in terms of gender. In this brief survey, healthy individuals with no prior non-communicable diseases were categorized as males (n=34) and females (n=43), and all samples were evaluated for plasma HER-2 levels at once. Surprisingly, the plasma level of HER-2 of healthy male individuals (mean= 2.28 ± 0.21 ng/mL) was significantly (P<0.0001) higher than the plasma level of HER-2 of healthy females (mean: 0.06 ± 0.09 ng/mL), with no overlap. Therefore, we suggest that more studies are required to re-check the cutoff values for HER-2 plasma levels based on gender since the clinical implications of a unique HER-2 cutoff for both genders may be seriously concerning. © 2023 Royan Institute (ACECR). All rights reserved.